Edition:
United States

Spectrum Pharmaceuticals Inc (SPPI.OQ)

SPPI.OQ on NASDAQ Stock Exchange Global Select Market

4.72USD
23 Sep 2016
Change (% chg)

$-0.09 (-1.87%)
Prev Close
$4.81
Open
$4.82
Day's High
$4.86
Day's Low
$4.68
Volume
193,564
Avg. Vol
216,029
52-wk High
$7.73
52-wk Low
$4.14

Select another date:

Wed, Sep 14 2016

Spectrum bladder cancer drug not effective: U.S. FDA panel

Spectrum Pharmaceuticals Inc's experimental bladder cancer treatment apaziquone is not effective in delaying the time to recurrence of the disease, an advisory committee to the U.S. Food and Drug Administration concluded on Wednesday.

Spectrum bladder cancer drug not effective - U.S. FDA panel

Sept 14 Spectrum Pharmaceuticals Inc's experimental bladder cancer treatment apaziquone is not effective in delaying the time to recurrence of the disease, an advisory committee to the U.S. Food and Drug Administration concluded on Wednesday.

BRIEF-Spectrum Pharmaceuticals says PDUFA date set for Qapzola NDA is Dec. 11

* FDA advisory committee votes that Qapzola (apaziquone) has not shown substantial evidence of a treatment effect over placebo

BRIEF-Spectrum Pharma Q2 non-gaap loss per share $0.05

* Q2 earnings per share view $-0.29 -- Thomson Reuters I/B/E/S

BRIEF-Spectrum says unit Allos Therapeutics and Fresenius Kabi USA reach settlement to resolve patent litigation

* Spectrum says unit Allos Therapeutics and Fresenius Kabi USA entered into settlement agreement to resolve patent litigation relating to Folotyn

BRIEF-Spectrum Pharmaceuticals' unit, Allos Therapeutics and Sandoz enter settlement agreement

* On June 8, 2016, co's unit , Allos Therapeutics and Sandoz Inc entered into a settlement agreement

D.C. Circuit will not to block generic version of Spectrum's Fusilev

By Brendan Pierson A federal appeals court has refused to block Novartis AG unit Sandoz Inc from making a generic version of Spectrum Pharmaceuticals Inc's drug Fusilev, which is used to counteract the toxic effects of a widely used chemotherapy drug.

BRIEF-Spectrum Pharma says Dr Reddy's will be permitted to market generic version of Folotyn in US on Dec 1, 2022 or earlier

* Co's unit, dr. Reddy's labs, ltd entered into settlement agreement to resolve their patent litigation relating to folotyn

BRIEF-Spectrum Pharma says unit, Teva enter settlement agreement

* Unit, teva pharmaceuticals usa, inc. Entered into settlement agreement to resolve patent litigation relating to Folotyn

BRIEF-Spectrum Pharmaceuticals Q1 loss per share $0.14

* Spectrum Pharmaceuticals reports first quarter 2016 financial results and pipeline update

Select another date: